Ascendis Pharma A/S Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
18analysts covering
FY EPS (est.)
$11.65next fiscal year
Monitoring Framework
Key Performance Indicators
YORVIPATH (palopegteriparatide) Global Revenue Quarterly197MTarget: Sequential growth in Q2 2026 as Q1 headwinds reverse
SKYTROFA (lonapegsomatropin) Global Revenue Quarterly44MTarget: Stable revenue for the full year 2026
YUVIWEL (navepegritide) U.S. Patient Enrollments Quarterly60.0Target: Strong early commercial uptake following April 2026 launch
Total Cash and Cash Equivalents Quarterly573MTarget: Adequate funding for near-term development and commercialization
Watch Items
- YUVIWEL (navepegritide) European Union Regulatory DecisionTrigger: EMA decision expected in Q4 2026Action: Monitor regulatory feedback and prepare for European commercial launch infrastructure if approved.
- TransCon CNP Phase 3 Trial in HypochondroplasiaTrigger: Trial initiation planned for H2 2026Action: Track clinical trial registry updates and patient enrollment milestones.
- Guidance Update and Operating Cash Flow TargetsTrigger: Guidance update to be provided after Q2 2026Action: Evaluate updated financial models and cash burn projections against the previous target of €500 million operating cash flow.
Research as of 2 Sep 2026